Pazopanib Tablet, Film Coated
Product Images NDC 13668-735

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Pazopanib (NDC 13668-735). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

400 mg (Bottle of 30 Tablets)

This text appears to be a description of medication tablets with specific dosage information (400 mg) and instructions for storage. The tablets contain Pazopanib Hydrochloride equivalent to 400 mg of Pazopanib free base. The National Drug Code (NDC) is mentioned as 13665-735-30. Storage instructions include keeping the tablets at 20°C to 25°C (68°F to 77°F) and not using them if the safety seal is broken. The tablets are indicated for use in a controlled room temperature environment. The manufacturer appears to be listed at the bottom as Prama B with an address in Bushuua.*

FDA Label Image

Chemical Structure (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 01)

FDA Label Image

Figure-1 (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 02)

This text provides data on the proportion of progression-free patients in a clinical study comparing Pazopanib tablets to a placebo. The results show that the median progression-free period for the Pazopanib group was 9.2 months compared to 4.2 months for the placebo group. The hazard ratio of 0.46 indicates a significantly lower risk of progression in the Pazopanib group. The results are statistically significant with a p-value of less than 0.001.*

FDA Label Image

Figure-2 (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 03)

This description provides information on the proportion of progression-free patients in a clinical study comparing Pazopanib tablets with a placebo. The study involved 246 patients taking Pazopanib and 123 patients taking the placebo. The median progression-free survival was 4.6 months for Pazopanib and 1.6 months for the placebo group. The hazard ratio was 0.35 with a 95% confidence interval of 0.26 to 0.48, indicating a significant difference between the two groups (p-value <0.001).*

FDA Label Image

Torrent Logo (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 04)

FDA Label Image

Image (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 167 2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.